Philip D. Greenberg
Immunologist who spent four decades engineering T cells to attack leukaemia and solid tumours.
Pioneer of T-cell receptor-engineered cell therapy, including WT1-specific TCR-T for AML after transplant and mesothelin-directed TCR-T for pancreatic cancer. Past president of AACR.
| Title | Journal | Year |
|---|---|---|
| T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant | Nature Medicine | 2019 |
| Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells | Advances in Immunology | 1991 |
Pages like this
not linked directly; found by shared links- PersonRaffit Hassan
- PersonHans-Peter Kiem
Shares Fred Hutchinson Cancer Center, Acute myeloid leukaemia.
- IdeaShared splice-derived neoantigens as off-the-shelf vaccine targets
Shares Fred Hutchinson Cancer Center, TCR-T cell therapy, Acute myeloid leukaemia.
- InstitutionIRCCS Ospedale San Raffaele
Shares TCR-T cell therapy, Acute myeloid leukaemia, CAR-T cell therapy, Pancreatic ductal adenocarcinoma.
- PersonAntoni Ribas
Shares American Association for Cancer Research (AACR), TCR-T cell therapy.
- TargetMUC16 (CA-125)
Shares Mesothelin, CAR-T cell therapy, Pancreatic ductal adenocarcinoma.
- IdeaRegionally delivered mesothelin CAR-T with PD-1 blockade
Shares Mesothelin, CAR-T cell therapy.
- IdeaPublic cell-therapy foundries at cancer centres for academics and start-ups
Shares TCR-T cell therapy, CAR-T cell therapy.